Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 37Completed 15Not yet recruiting 13Unknown 11Terminated 11Active not recruiting 4Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 8Pancreatic Neoplasms 4Myelodysplastic Syndromes 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Stomach Neoplasms 2Recurrence 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Vaginitis 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Advanced Solid Tumors × Clear all
NCT01226056 2010-10-21

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Southern Europe New Drug Organization

Phase 1/2 Suspended
45 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡